Boston Scientific (BSX) fundamentals: P/E, valuation, undervalued?
Boston Scientific · Health Care · ref. ETF XLV · price $43.31
In short — Boston Scientific trades at 17.8× earnings (P/E), 12.8× forward, with a net margin of 17.5 % and revenue growth of +8 %. Read: Cheap for the growth (P/E 13 for ~15% growth (PEG 0.8)).
Is Boston Scientific stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$43.31-55.0% over range
Oct 14, 25low $41.58 · high $104.98Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
76% recommend buying · 21 analysts
Valuation : Cheap for the growth — P/E 13 for ~15% growth (PEG 0.8)
Valuation
17.8
P/E (price/earnings)
12.8
Forward P/E
1.18
PEG
2.5
Price/book (P/B)
$62.8B
Market cap
2.44
EPS
Profitability & growth
17.5 %
Net margin
+8 %
Revenue growth
+15 %
Earnings growth
$12.6B
Total debt
Boston Scientific income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $12.7B | $642M | 5.1 % |
| 2023 | $14.2B | $1.6B | 11.0 % |
| 2024 | $16.7B | $1.9B | 11.1 % |
| 2025 | $20.1B | $2.9B | 14.4 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Boston Scientific's P/E and is the stock undervalued? What's a good P/E?
Boston Scientific's P/E is 17.8 (forward 12.8). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Boston Scientific profitable?
Boston Scientific has a net margin of 17.5 % (EPS 2.44). The company is profitable.
Is BSX stock expensive?
Our read: "Cheap for the growth" — P/E 13 for ~15% growth (PEG 0.8). Cross-check with growth and sector.
💬 A question about Boston Scientific? The JPI assistant answers using our backtest data.